<DOC>
	<DOCNO>NCT01758289</DOCNO>
	<brief_summary>This study design evaluate effectiveness , safety , impact quality life paricalcitol ( Zemplar® intravenous [ IV ] ) administer Venezuelan patient hemodialysis risk develop secondary hyperparathyroidism associate stage V chronic kidney disease .</brief_summary>
	<brief_title>Post Marketing Observational Study Paricalcitol IV Administered Venezuelan Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Male female ≥ 18 year old document diagnosis stage V chronic kidney disease , hemodialysis study baseline Subjects previously treat vitamin D metabolites naïve paricalcitol Subjects use paricalcitol clinically indicate document applicable routine standard healthcare ( i.e . laboratory assessment clinical evaluation ) accord criterion attend physician accordance approve label product Venezuela Subjects provide write informed consent form state his/her authorization willingness participate study allow use discussion his/her personal and/or health information enter study Female subject reproductive potential must use approved contraceptive method ( intrauterine device , birth control pills barrier device ) three ( 03 ) month discontinuation treatment Subjects severe hyperparathyroidism ( parathyroid hormone [ PTH ] &gt; 3000 pg/mL ) Subjects hypercalcemia , adjust accord serum albumin , hyperphosphatemia , subject calciumphosphorus product ( Ca x P ) ≥ 70 Known hypersensitivity and/or toxicity vitamin D , metabolites and/or component Zemplar® IV ( paricalcitol ) Subjects participated clinical trial within 30 day start study currently enrol clinical trial treatment investigational product Subjects tolerate take phosphate binder contain calcium and/or aluminum Subjects opinion investigator , reason ( include medical reason ) eligible and/or appropriate therapy synthetic analog vitamin D and/or unwilling complete study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Venezuelan Patients</keyword>
	<keyword>Depressive Symptoms</keyword>
	<keyword>Health Related Quality Life</keyword>
</DOC>